Abstract 206TiP
Background
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is frequently diagnosed at an advanced stage. In the phase 3 HIMALAYA study (NCT03298451) in unresectable HCC (uHCC), the STRIDE (Single Tremelimumab Regular Interval Durvalumab) regimen improved overall survival (OS) versus sorafenib, with a manageable safety profile. HIMALAYA enrolled participants with uHCC not eligible for embolisation with Barcelona Clinic Liver Cancer (BCLC) stage B or C, Child-Pugh (CP) class A, WHO/ECOG PS of 0-1 and no main trunk portal vein thrombosis (PVT). Based on the positive results of HIMALAYA, the aim of SIERRA is to assess the safety and efficacy of STRIDE in a broader uHCC population, including inferior hepatic function, poorer performance status or more advanced disease.
Trial design
SIERRA (NCT05883644) is a phase 3b, single-arm, multicentre study. This study will enroll approximately 140 adults with uHCC, BCLC stage B or C, and one of the following: CP class of B7 or B8 with WHO/ECOG PS of 0-1, without main trunk PVT; CP class A with WHO/ECOG PS of 2, without main trunk PVT; CP class A with WHO/ECOG PS of 0-1 with evidence of chronic main trunk PVT. Participants must not have received prior systemic therapy for HCC and must not be eligible for locoregional therapy. Key exclusion criteria include evidence of acute main trunk PVT. All participants will receive STRIDE: one single priming dose of 300 mg tremelimumab plus 1500 mg durvalumab at Day 1 (Week 0), followed by durvalumab 1500 mg monotherapy Q4W starting at Week 4 and continuing until clinical progression, confirmed radiological progression (RECIST 1.1), unacceptable toxicity, withdrawal of consent or any discontinuation criteria are met. The co-primary endpoints are the incidence of Grade 3 or 4 adverse events possibly related to study intervention within 6 months after initiation of STRIDE and investigator-assessed (RECIST 1.1) objective response rate. Secondary endpoints include OS, progression-free survival, duration of response and health-related quality of life. Enrolment has begun and will proceed in France, Germany, Italy, Japan, South Korea, Singapore, Spain, United States, Vietnam and Hong Kong.
Clinical trial identification
NCT05883644.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
S.L. Chan: Financial Interests, Personal, Advisory Board: Eisai, AstraZeneca, MSD, BMS, Roche; Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Eisai, Roche, Ipsen, BMS; Financial Interests, Personal, Research Grant: Eisai, MSD. B. Sangro: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Boston Scientific, Roche, Sirtex, Terumo, Bayer, Adaptimmune; Financial Interests, Personal, Invited Speaker: Roche, Sirtex, Eisai, Ipsen, Incyte, AstraZeneca, Astellas Pharma; Financial Interests, Institutional, Research Grant: BMS, Sirtex; Financial Interests, Personal, Coordinating PI: AstraZeneca; Financial Interests, Personal, Steering Committee Member: BMS, Boston Scientific, Roche. M. Kudo: Financial Interests, Personal, Invited Speaker: Eisai, Chugai, Eli Liiy, Bayer, Takeda, AstraZeneca; Financial Interests, Institutional, Research Grant: Otsuka, EA Pharma, Taiho, Eisai, AbbVie, GE Healthcare, Chugai. A. Dane: Financial Interests, Institutional, Speaker, Consultant, Advisor: Adagio, Amplyx, AN2, Bioscript, Bugworks, CARBX, Closed Loop Medicine, Correvio, Davolterra, Destiny, Evopoint, F2G, Entasis, Gates, GSK, Humanigen, Liverpool University, Kymab, Melinta, Modis, Orca, Phico, Quince, Roche, SFunga, Scynexis, Sinovent, SNIPR; Financial Interests, Institutional, Other, Independent statistician on DSMBs: Aridis, Cerium, ContraFect, Egetis, Midatech, Pfizer, Pled, Rare Thyroid, Sanofi, Transcrip. C. Emery: Financial Interests, Personal, Other, Contracted employee: AstraZeneca. M. Paskow: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. M. Makowsky: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. B. Nguyen: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. L. Rimassa: Financial Interests, Personal, Advisory Board, Consulting and advisory role: AstraZeneca, Basilea, Bayer, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, Zymeworks; Financial Interests, Personal, Invited Speaker, Lecture fees: AstraZeneca, Bayer, BMS, Incyte, Ipsen, Roche, Servier; Financial Interests, Personal, Other, Travel expenses: AstraZeneca; Financial Interests, Institutional, Steering Committee Member: Exelixis, Incyte, Ipsen, Nerviano Medical Sciences, Roche; Financial Interests, Institutional, Coordinating PI, National (Italian) coordinating PI: AstraZeneca, BeiGene, Zymeworks; Financial Interests, Institutional, Local PI: Agios, Eisai, Fibrogen, Lilly, MSD; Financial Interests, Institutional, Funding: Ipsen; Financial Interests, Institutional, Coordinating PI, European PI: AstraZeneca.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract